Retroviral vector production in the National Gene Vector Laboratory at Indiana University

Kenneth Cornetta, L. Matheson, C. Ballas

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The National Gene Vector Laboratory (NGVL) is a US National Institutes of Health initiative charged with providing clinical grade vectors for gene therapy trials. The program was started in 1995 and Indiana University has served as the production site for retroviral vectors and is also accepting applications for production of lentiviral vectors. The facility is designed to produce vectors for Phase I and Phase II clinical trials with the specific mandate to facilitate investigator-initiated research for academic institutions. To date, the facility has generated over 30 Master Cell Banks for gene therapy investigators throughout the United States. This required the facility to develop a system that can adapt to the varied needs of investigators, most of whom request different vector backbones, packaging cell lines, final product volumes, and media. In this review, we will illustrate some of the experiences of the Indiana University NGVL during the generation of retroviral vectors using murine-based packaging cell lines.

Original languageEnglish
JournalGene Therapy
Volume12
Issue numberSUPPL. 1
DOIs
StatePublished - Oct 2005

Fingerprint

Research Personnel
Product Packaging
Genetic Therapy
Genes
Cell Line
Phase II Clinical Trials
National Institutes of Health (U.S.)
Research

Keywords

  • Replication-competent retrovirus
  • Retroviral gene transfer
  • Vector production

ASJC Scopus subject areas

  • Genetics

Cite this

Retroviral vector production in the National Gene Vector Laboratory at Indiana University. / Cornetta, Kenneth; Matheson, L.; Ballas, C.

In: Gene Therapy, Vol. 12, No. SUPPL. 1, 10.2005.

Research output: Contribution to journalArticle

@article{ebda5f4f0ffe40d38d1426586ee54c64,
title = "Retroviral vector production in the National Gene Vector Laboratory at Indiana University",
abstract = "The National Gene Vector Laboratory (NGVL) is a US National Institutes of Health initiative charged with providing clinical grade vectors for gene therapy trials. The program was started in 1995 and Indiana University has served as the production site for retroviral vectors and is also accepting applications for production of lentiviral vectors. The facility is designed to produce vectors for Phase I and Phase II clinical trials with the specific mandate to facilitate investigator-initiated research for academic institutions. To date, the facility has generated over 30 Master Cell Banks for gene therapy investigators throughout the United States. This required the facility to develop a system that can adapt to the varied needs of investigators, most of whom request different vector backbones, packaging cell lines, final product volumes, and media. In this review, we will illustrate some of the experiences of the Indiana University NGVL during the generation of retroviral vectors using murine-based packaging cell lines.",
keywords = "Replication-competent retrovirus, Retroviral gene transfer, Vector production",
author = "Kenneth Cornetta and L. Matheson and C. Ballas",
year = "2005",
month = "10",
doi = "10.1038/sj.gt.3302613",
language = "English",
volume = "12",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Retroviral vector production in the National Gene Vector Laboratory at Indiana University

AU - Cornetta, Kenneth

AU - Matheson, L.

AU - Ballas, C.

PY - 2005/10

Y1 - 2005/10

N2 - The National Gene Vector Laboratory (NGVL) is a US National Institutes of Health initiative charged with providing clinical grade vectors for gene therapy trials. The program was started in 1995 and Indiana University has served as the production site for retroviral vectors and is also accepting applications for production of lentiviral vectors. The facility is designed to produce vectors for Phase I and Phase II clinical trials with the specific mandate to facilitate investigator-initiated research for academic institutions. To date, the facility has generated over 30 Master Cell Banks for gene therapy investigators throughout the United States. This required the facility to develop a system that can adapt to the varied needs of investigators, most of whom request different vector backbones, packaging cell lines, final product volumes, and media. In this review, we will illustrate some of the experiences of the Indiana University NGVL during the generation of retroviral vectors using murine-based packaging cell lines.

AB - The National Gene Vector Laboratory (NGVL) is a US National Institutes of Health initiative charged with providing clinical grade vectors for gene therapy trials. The program was started in 1995 and Indiana University has served as the production site for retroviral vectors and is also accepting applications for production of lentiviral vectors. The facility is designed to produce vectors for Phase I and Phase II clinical trials with the specific mandate to facilitate investigator-initiated research for academic institutions. To date, the facility has generated over 30 Master Cell Banks for gene therapy investigators throughout the United States. This required the facility to develop a system that can adapt to the varied needs of investigators, most of whom request different vector backbones, packaging cell lines, final product volumes, and media. In this review, we will illustrate some of the experiences of the Indiana University NGVL during the generation of retroviral vectors using murine-based packaging cell lines.

KW - Replication-competent retrovirus

KW - Retroviral gene transfer

KW - Vector production

UR - http://www.scopus.com/inward/record.url?scp=27544432164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27544432164&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3302613

DO - 10.1038/sj.gt.3302613

M3 - Article

VL - 12

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - SUPPL. 1

ER -